Conditions: 97.1% · liraglutide · BCH.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
What should I decide now, and what should I defer?
97.1 per cent purity with no content figure leaves the milligram number unmeasured. Purity says 97.1 of every 100 units of detected area is liraglutide and 2.9 is something else. Content says how many milligrams are in the glass. The two do not constrain each other: a vial can be 97.1 per cent pure and still be under label, because water and counter-ion are part of the gross mass and neither shows up as an impurity peak. If you buy one test, buy the one that changes your arithmetic.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 8 Jul 2025 by dmitri_savchuk — added the placebo-arm figures
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe underlying point is that gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
In practice, the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
Compare purity within a single laboratory on the same method, never across laboratories.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The relevant detail is that reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
edited 5 Sept 2025 by tare_weight — added the method parameters
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.